Press Release

Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologies for Improving Drug Solubility and Bioavailability

Boonton, NJ – April 4, 2022 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that CEO, Rajiv Khosla, Ph.D., was featured in Drug Development and Delivery discussing the ability of Enteris’ Peptelligence® and ProPerma® technologies to overcome the permeability and solubility issues that prevent the oral delivery of many “beyond the rule of 5” (bRo5) compounds, including peptides, peptidomimetics, and intermediate-sized small molecule compounds.


    EnterisBioPharma is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

    You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

    By clicking submit below, you consent to allow EnterisBioPharma to store and process the personal information submitted above to provide you the content requested.

    Meet Enteris Biopharma at CPhI North America 2022

    May 17-19, Philadelphia, PA


    To learn more about our technologies and CMO service offerings please fill out and submit the form.

      How did you hear about us?*

      I am interested in: